-
DiscoveryBreaking a vicious cycle of inflammation
Novartis researchers aim to quash inflammation to treat chronic disease.
Discovery -
DiscoveryHelping clinical trial patients during a lockdown
Yan Zhao talks about how her team in China responded to an emerging public health crisis.
Discovery -
DiscoveryMoving from speculation to science during a pandemic
Florencia Segal’s experiences prepared her to lead the rapid design of a large COVID-19 clinical trial.
Discovery -
DiscoveryIt takes an R&D village to fight a pandemic
Gervais Tougas shares his experience working on a Novartis task force dedicated to fighting the COVID-19 pandemic.
Discovery -
DiscoveryCOVID-19: Answering your top questions
Novartis CEO Vas Narasimhan answers questions about COVID-19.
Discovery -
DiscoveryVisualizing molecular glues
Molecular glues are a new type of medicine inspired by nature’s matchmakers.
Discovery -
DiscoveryThe data42 program shows Novartis’ intent to go big on data and digital
Novartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.
Discovery -
DiscoveryMeet Achim, leading the data42 program
The recently appointed leader of the Novartis’ digital research and development platform data42 is a strong believer that data and digital technologies will change the path of medical science.
Discovery -
DiscoveryClinical trial comes together in weeks to address coronavirus
Researchers race to put hydroxychloroquine to the test in a large study.
Discovery -
DiscoveryShaping the future of sickle cell disease
Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.
Discovery -
DiscoverySourcing innovation, strategically
Phil Gotwals talks about his vision for the future of business development for research.
Discovery -
DiscoveryA decades-long journey in blood cancer research
Novartis immunologist describes the excitement of discovering a promising new immuno-oncology (IO) target in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Discovery